(CercleFinance.com) – GSK announced Monday that the European Commission had approved the marketing of its immunotherapy Jemperli in the first-line treatment of endometrial cancer.
In a press release, the British laboratory specifies that the authorization from Brussels concerns the combination of Jemperli and chemotherapy in the treatment of advanced or recurrent endometrial cancer with dMMR/MSI status.
This is the first immunotherapy approved for this indication.
GSK indicates that the European Union has also decided to consider as definitive the conditional monotherapy authorization that it had previously granted to Jemperli in the second-line treatment of endometrial cancer.
Initially discovered by the American AnaptysBio, Jemperli has been the subject of a licensing agreement since 2014 with Tesaro, since bought by GSK, which is now called upon to ensure its development and marketing.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
